5-(1-Methylpropyl)-1,3-benzodioxole | 108303-54-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 5-(1-Methylpropyl)-1,3-benzodioxole
• 英文别名: 5-butan-2-yl-1,3-benzodioxole
• CAS: 108303-54-4
• 化学式: C₁₁H₁₄O₂
• 分子量: 178.23
• InChiKey: PBIPTQSGZRQISQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS
  申请人：HADIDA RUAH SARA S.

  公开号：US20090143381A1

  公开（公告）日：2009-06-04

  Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药用可接受的组合物可用作ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节蛋白（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。
• 5-(Arylsulfonyl)-Pyrazolopiperidines
  申请人：Ye Xiaocong Michael

  公开号：US20100267747A1

  公开（公告）日：2010-10-21

  The invention provides N-cyclic sulfonamido compounds of Formula I wherein A, B, R 1 , R 1a , R 2 , R 2a , R 3 and R 3a are as described in the specification. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of preparing compounds of formula I, and methods of treating cognitive disorders, such as Alzheimer's disease.

  本发明提供了公式I的N-环磺酰胺化合物，其中A、B、R1、R1a、R2、R2a、R3和R3a如规范所述。公式I的化合物对于治疗或预防认知障碍，如阿尔茨海默病，是有用的。本发明还包括包含公式I的化合物的制药组合物，制备公式I的化合物的方法以及治疗认知障碍，如阿尔茨海默病的方法。
• Modulators of ATP-Binding Cassette Transporters
  申请人：Hadida-Ruah Sara

  公开号：US20120232059A1

  公开（公告）日：2012-09-13

  Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药学上可接受的组合物，可用作ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜电导调节因子（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。
• Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
  申请人：XW LABORATORIES INC.

  公开号：US10774031B2

  公开（公告）日：2020-09-15

  The present disclosure discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.

  本公开披露了γ-羟丁酸的原药及其组合物和用途。
• 1-(BENZO[D][1,3]DIOXOL-5-YL)-N-(PHENYL)CYCLOPROPANE-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS FOR THE TREATMENT OF CYSTIC FIBROSIS
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP2016065B1

  公开（公告）日：2012-09-19